Children's Hospital of Philadelphia-ko ikertzaileekin lankidetzan egindako argitalpenak (6)

2021

  1. A g316a polymorphism in the ornithine decarboxylase gene promoter modulates mycn‐driven childhood neuroblastoma

    Cancers, Vol. 13, Núm. 8

2020

  1. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report from the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group

    Journal of Clinical Oncology, Vol. 38, Núm. 31, pp. 3685-3697

2018

  1. Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients

    JCI insight, Vol. 3, Núm. 23

  2. Genomic amplifications and distal 6q loss: Novel markers for poor survival in high-risk neuroblastoma patients

    Journal of the National Cancer Institute, Vol. 110, Núm. 10

2011

  1. miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples

    Clinical Cancer Research, Vol. 17, Núm. 24, pp. 7684-7692

2009

  1. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study

    The Lancet Oncology, Vol. 10, Núm. 7, pp. 663-671